DOCSLIB.ORG

Family Planning Manual

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Family Planning Manual Iowa Department of Public Health Family Planning Manual Updated September 2019 100 -- CONTENTS OF SECTION PURPOSE OF THE FAMILY PLANNING MANUAL ........................................................... 101-1 MAINTENANCE OF THE IDPH FAMILY PLANNING MANUAL ........................................ 102-1 FAMILY PLANNING ORGANIZATIONAL STRUCTURE ................................................... 103-1 ORIENTATION POLICY FOR NEW FAMILY PLANNING DIRECTORS ............................ 104-1 ORIENTATION POLICY FOR NEW MATERNAL CHILD HEALTH ADVISORY COMMITTEE MEMBERS AND MEDICAL ADVISORY COMMITTEE MEMBERS ................................... 105-1 ORIENTATION POLICY FOR NEW BUREAU OF FAMILY HEALTH STAFF .................... 106-1 POLICY FOR NEW SUB RECIPIENT STAFF ORIENTATION AND ANNUAL REQUIRED STAFF TRAINING .............................................................................................................. 107-1 Iowa Department of Public Health Title X Family Planning Services Manual - Updated September 2019 SECTION: SUBJECT: NUMBER: Introduction Purpose 101 Implementation Revision Date: July 2019 Title X Status: Cross Reference: Family Planning Authority: Services Public Health Service Act 42 CFR Part 59; IAC 641-74; Program Manual Requirements for Title X Funded FP Projects, 2014; QFP, 2014 PURPOSE OF THE FAMILY PLANNING MANUAL This manual contains information necessary for providing family planning and reproductive health services as part of the Iowa Department of Public Health Family Planning (FP) program. It provides the basis for the development of business practices and programming for FP services. The manual is intended for use by agencies, which contract with the Iowa Department of Public Health, for federal Title X funds to provide family planning services in local communities. The manual outlines federal and state policies and procedures applicable to all contract agencies. Access to this manual must be available at all clinic sites. The FP manual is accessible via the IDPH website at: http://idph.iowa.gov/Portals/1/userfiles/38/100s%20through%20400s.pdf IOWA MEDICAID ENTERPRISE MANUAL FOR FAMILY PLANNING The FP services provider manual is the Iowa Department of Human Service’s (IDHS) official interpretation of the federal laws and regulations and the state laws and rules relating to the programs it administers. The purpose of the manual is to present IDHS policies and procedures for program administration in a centralized and usable form. The manual provides the official record of IDHS’s interpretation of the policies adopted in its rules and authorizing legislation. IDPH contractors must be in compliance with the manual for the provision and billing of FP services. Iowa DHS FP services manual can be found at: https://dhs.iowa.gov/sites/default/files/5-F.pdf?090120191848 101-1 Iowa Department of Public Health Title X Family Planning Services Manual - Updated September 2019 SECTION: SUBJECT: NUMBER: Introduction Maintenance of the IDPH FP Manual 102 Implementation Revision Date: July 2019 Title X Status: Cross Reference: Family Planning Authority: Services Public Health Service Act 42 CFR Part 59; IAC 641-74; Program Manual Requirements for Title X Funded FP Projects, 2014; QFP, 2014 MAINTENANCE OF THE IDPH FAMILY PLANNING MANUAL The manual contains sections dealing with program administration, clinical policies, quality assurance, and a large appendix. In order for it to fulfill its purpose, the manual must be properly maintained. The clinical portion of the manual is reviewed and revised annually as appropriate by the Family Planning (FP) Medical Advisory Committee. The rest of the manual is reviewed by the program director every three years or when necessary to reflect changes in federal or state requirements. Links to websites that appear in the manual will be checked annually. The scheduled revision process does not preclude revisions that might be needed at other times. Manual users, state and local, may request consideration of manual revisions at any time through the family planning director. Policies that are retired will be identified as such in the table of contents and in a blank policy page within the manual. Every effort is made to distribute manual revisions as soon as they are completed annually. This may be done in hard copy or electronic form. The FP manual is also available online at: http://idph.iowa.gov/Portals/1/userfiles/38/100s%20through%20400s.pdf. Sub-recipient agencies will follow the same manual review schedule as IDPH. 102-1 Iowa Department of Public Health Title X Family Planning Services Manual - Updated September 2019 SECTION: SUBJECT: NUMBER: Introduction FP Organizational Structure 103 Implementation Revision Date: July 2019 Title X Status: Cross Reference: Family Planning Authority: Services Public Health Service Act 45 CFR Part 59; MCHS Administrative Manual Manual; IAC 641-74 FAMILY PLANNING ORGANIZATIONAL STRUCTURE The Family Planning (Title X) program is administered by the Iowa Department of Public Health (IDPH), Division of Health Promotion and Chronic Disease Prevention, Bureau of Family Health, pursuant to an agreement with the United States Department of Health and Human Services, Office of Population Affairs. IOWA DEPARTMENT OF PUBLIC HEALTH Under the leadership of the director, the IDPH exercises general supervision of the state’s public health; promotes public hygiene and sanitation; does health promotion activities; prepares for and responds to bioemergency situations; and unless otherwise provided, enforces laws on public health. The IDPH programs are conducted through the executive staff and the following divisions: • Acute Disease Prevention, Emergency Response, and Environmental Health • Administration and Professional Licensure • Behavioral Health • Health Promotion and Chronic Disease Prevention • Tobacco Use Prevention and Control The Director’s office focuses primarily on the overall development of health related policy, strategic planning and outcome. The Iowa State Board of Health is the policy-making body for the IDPH. It has the powers and duties to adopt, promulgate, amend and repeal rules and regulations, and advises or makes recommendations to the governor, general assembly, and the IDPH director, on public health, hygiene and sanitation. Division of Health Promotion and Chronic Disease Prevention The Division of Health Promotion and Chronic Disease Prevention promotes and supports healthy behaviors and communities, the prevention and management of chronic diseases, the development of public health infrastructure and access to health care/services at local and state levels. • Bureau of Nutrition and Physical Activity • Bureau of Oral & Health Delivery Systems • Bureau of Family Health • Bureau of Chronic Disease Prevention & Management Bureau of Family Health The Bureau of Family Health is responsible for administering the portion of the Title X Grant that comes to the IDPH. The bureau uses the core public health functions to fulfill its responsibility for infrastructure building, population-based services, enabling services and direct health care 103-1 Iowa Department of Public Health Title X Family Planning Services Manual - Updated September 2019 services for the health of women and children. The bureau has the primary responsibility for system planning, program development and evaluation; developing and monitoring standards of care; and coordinating health-related services between and among community-based entities serving Iowa women. The bureau has multiple programs focusing on the health of women, children and families including: Maternal and Child Health Title V programs, Family Planning Title X programs, Healthy Child Care Iowa, Covering Kids and Families, Hawki, Early Periodic Screening Diagnosis and Treatment (EPSDT), Early Hearing Detection and Intervention, Iowa Infant Mortality Prevention Center, the Statewide Perinatal Care Program, and the programs of the Center for Congenital and Inherited Disorders, Personal Responsibility Education Program (PREP), Abstinence Education Program, Pregnancy Risk Assessment Monitoring System (PRAMS), and Maternal, Infant, and Early Childhood Home Visitation Program. The programs within the bureau work closely together and provide in-kind support to one another. Family Planning staff work closely with the staff of the Bureau of HIV, STD and Hepatitis on the Community Based Screening Services (CBSS) project and the Women’s Health Team. In addition to the Core Public Health Functions (published in the 1988 Institute of Medicine Report) and the Ten Essential Public Health Services to Promote Maternal and Child Health in America, the Bureau uses the Title X National Priorities to develop overall goals, for oversight and management of the Family Planning programs. Those goals can be found online at http://www.hhs.gov/opa/title-x-family-planning/title-x-policies/program-priorities/. OTHER STATE DEPARTMENTS Programs in other departments or entities of state government that serve Iowa women include, but are not limited to, the following: • The Iowa Department of Human Services Administers services for mental health, developmental disabilities, child welfare, child care, child abuse and neglect, Title XIX (Medicaid) program, Family Planning Program, Title XXI state child health insurance program, and pregnancy prevention grants. NON-STATE FUNDED RELATIONSHIPS The IDPH FP staff has had a long and collaborative relationship with the Family Planning Council of Iowa (FPCI). FPCI is the other Title X grantee
Load more

Recommended publications
  • Patch Development with New Drugs Versus Generic Development – Principles and Methods
    Patch development with new drugs versus generic development – principles and methods Dr. Barbara Schug SocraTec R&D, Oberursel , Germany www.socratec-pharma.de AGAH Workshop, The new European modified Release Guideline- from cook book to interpretation, Bonn, June 15th –16th, 2015 Some basics Physico-chemical properties / conventional patches small molecule < 500kDa lipophilic potent therapeutic concept which requires low fluctuation Skin controls release rate drug substance dispersed in adhesive matrix Patch controls release rate rate controlling membrane between drug reservoir and skin Currently marketed patches Year Generic (Brand) Names Indication 1979 Scopolamine (Transderm Scop®) Motion sickness 1982 Nitroglycerine (Nitroderm TTS) Angina pectoris 1984 Clonidine (Catapress TTS®) Hypertension 1986 Estradiol (Estraderm®) Menopausal symptoms 1990 Fentanyl (Duragesic®) Chronic pain 1991 Nicotine (Nicoderm®, Habitrol®, Prostep®) Smoking cessation 1993 Testosterone (Androderm®) Testosterone deficiency 1995 Lidocaine/epinephrine (Iontocaine®) Local dermal analgesia 1998 Estradiol/norethindrone (Combipatch®) Menopausal symptoms 1999 Lidocaine (Lidoderm®) Post-herpetic neuralgia pain 2001 Ethinyl estradiol/norelgestromin (OrthoEvra®) Contraception 2003 Estradiol/levonorgestrel (Climara Pro®) Menopause 2003 Oxybutynin (Oxytrol®) Overactive bladder 2004 Lidocaine/ultrasound (SonoPrep®) Local dermal anesthesia Source: modified from Wilson EJ, Three Generations: The Past, Present, and Future of Transdermal Drug Delivery Systems, May 2014
    [Show full text]
  • F.8 Ethinylestradiol-Etonogestrel.Pdf
    General Items 1. Summary statement of the proposal for inclusion, change or deletion. Here within, please find the evidence to support the inclusion Ethinylestradiol/Etonogestrel Vaginal Ring in the World Health Organization’s Essential Medicines List (EML). Unintended pregnancy is regarded as a serious public health issue both in developed and developing countries and has received growing research and policy attention during last few decades (1). It is a major global concern due to its association with adverse physical, mental, social and economic outcomes. Developing countries account for approximately 99% of the global maternal deaths in 2015, with sub-Saharan Africa alone accounting for roughly 66% (2). Even though the incidence of unintended pregnancy has declined globally in the past decade, the rate of unintended pregnancy remains high, particularly in developing regions. (3) Regarding the use of contraceptive vaginal rings, updated bibliography (4,5,6) states that contraceptive vaginal rings (CVR) offer an effective contraceptive option, expanding the available choices of hormonal contraception. Ethinylestradiol/Etonogestrel Vaginal Ring is a non-biodegradable, flexible, transparent with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. Ethinylestradiol/Etonogestrel Vaginal Ring is intended for women of fertile age. The safety and efficacy have been established in women aged 18 to 40 years. The main advantages of CVRs are their effectiveness (similar or slightly better than the pill), ease of use without the need of remembering a daily routine, user ability to control initiation and discontinuation, nearly constant release rate allowing for lower doses, greater bioavailability and good cycle control with the combined ring, in comparison with oral contraceptives.
    [Show full text]
  • Wellness Benefits
    Wellness Benefits University of South Alabama This schedule outlines services and items that the University of South Alabama considers a preventive service under this plan. These services must be performed by a physician in the University of South Alabama Health System provider network or by a dermatologist, endocrinologist, durable medical equipment provider, ancillary service provider, urologist, or rheumatologist provider (as applicable) in the entire VIVA HEALTH network. Many of these services are provided as part of an annual physical. This list does not apply to all VIVA HEALTH plans. Please refer to your Summary Plan Description to determine the terms of your health plan. PREVENTIVE SERVICE FREQUENCY/LIMITATIONS Well Baby Visits (Age 0-2) As recommended per guidelines1 Routine screenings, tests, and immunizations As recommended per guidelines Well Child Visits (Age 3-17) One per year at PCP2 Routine screenings, tests, & immunizations As recommended per guidelines HIV screening and counseling As recommended per guidelines Obesity screening As recommended per guidelines Hepatitis B virus screening As recommended per guidelines Sexually transmitted infection counseling Annually Skin cancer behavioral counseling (Beginning at age 10) As recommended per guidelines Routine Physical (Age 18+) One per year at PCP2 Alcohol misuse screening and counseling Annually Blood pressure screening Annually Cholesterol screening As recommended per guidelines Depression screening Annually Diabetes screening As recommended per
    [Show full text]
  • Vaginal Administration of Contraceptives
    Scientia Pharmaceutica Review Vaginal Administration of Contraceptives Esmat Jalalvandi 1,*, Hafez Jafari 2 , Christiani A. Amorim 3 , Denise Freitas Siqueira Petri 4 , Lei Nie 5,* and Amin Shavandi 2,* 1 School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK 2 BioMatter Unit, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50-CP 165/61, 1050 Brussels, Belgium; [email protected] 3 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium; [email protected] 4 Fundamental Chemistry Department, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, São Paulo 05508-000, Brazil; [email protected] 5 College of Life Sciences, Xinyang Normal University, Xinyang 464000, China * Correspondence: [email protected] (E.J.); [email protected] (L.N.); [email protected] (A.S.); Tel.: +32-2-650-3681 (A.S.) Abstract: While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well- established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy.
    [Show full text]
  • Recommendations for Contraceptive Use, 2013 Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2Nd Edition
    Morbidity and Mortality Weekly Report Early Release / Vol. 62 June 14, 2013 U.S. Selected Practice Recommendations for Contraceptive Use, 2013 Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Edition Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html. U.S. Department of Health and Human Services Centers for Disease Control and Prevention Early Release CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Appendix A: Summary Chart of U.S. Medical Eligibility Criteria for Methods ....................................................................................................................2 Contraceptive Use, 2010 .................................................................................. 47 How To Use This Document ...............................................................................3 Appendix B: When To Start Using Specific Contraceptive Summary of Changes from WHO SPR ............................................................4 Methods .............................................................................................................. 55 Contraceptive Method Choice .........................................................................4 Appendix C: Examinations and Tests Needed Before Initiation of Maintaining Updated Guidance ......................................................................4 Contraceptive Methods
    [Show full text]
  • Biomedical Technology and Devices Handbook
    1140_bookreps.fm Page 1 Tuesday, July 15, 2003 9:47 AM 29 Pharmaceutical Technical Background on Delivery Methods CONTENTS 29.1 Introduction 29.2 Central Nervous System: Drug Delivery Challenges to Delivery: The Blood Brain Barrier • Indirect Routes of Administration • Direct Routes of Administration 29.3 Cardiovascular System: Drug Delivery Chronotherapeutics • Grafts/Stents 29.4 Orthopedic: Drug Delivery Metabolic Bone Diseases 29.5 Muscular System: Drug Delivery 29.6 Sensory: Drug Delivery Ultrasound • Iontophoresis/Electroporation 29.7 Digestive System: Drug Delivery GI Stents • Colonic Drug Delivery 29.8 Pulmonary: Drug Delivery Indirect Routes of Administration • Direct Routes of Robert S. Litman Administration Nova Southeastern University 29.9 Ear, Nose, and Throat: Drug Delivery Maria de la Cova The Ear • The Nose • The Throat 29.10 Lymphatic System: Drug Delivery Icel Gonzalez 29.11 Reproductive System: Drug Delivery University of Memphis Contraceptive Implants • Contraceptive Patch • Male Contraceptive Eduardo Lopez References 29.1 Introduction In the evolution of drug development and manufacturing, drug delivery systems have risen to the forefront in the latest of pharmaceutical advances. There are many new pharmacological entities discov- ered each year, each with its own unique mechanism of action. Each drug will demonstrate its own pharmacokinetic profile. This profile may be changed by altering the drug delivery system to the target site. In order for a drug to demonstrate its pharmacological activity it must be absorbed, transported to the appropriate tissue or target organ, penetrate to the responding subcellular structure, and elicit a response or change an ongoing process. The drug may be simultaneously or sequentially distributed to a variety of tissues, bound or stored, further metabolized to active or inactive products, and eventually © 2004 by CRC Press LLC 1140_bookreps.fm Page 2 Tuesday, July 15, 2003 9:47 AM 29-2 Biomedical Technology and Devices Handbook excreted from the body.
    [Show full text]
  • VTE Prophylaxis in Gynecologic Surgery
    ClinicalProviding Information Evidence-based for 25 Years AHC Media LLC Home Page—www.ahcmedia.com CME for Physicians—www.cmeweb.com EDITOR VTE Prophylaxis in Gynecologic Jeffrey T. Jensen, MD, MPH Leon Speroff Professor and Vice Chair for Research Surgery: Quo Vadis? Department of Obstetrics and Gynecology ABSTRACT & COMMENTARY Oregon Health & Science University InsIde Portland Oligohydram- By Robert L. Coleman, MD ASSOCIATE EDITORS nios: A reason Sarah L. Berga, MD Professor and Chair to deliver? Professor, University of Texas; M.D. Anderson Cancer Center, Houston Department of Obstetrics and page 59 Gynecology Vice President for Women’s Dr. Coleman reports no financial relationships relevant to this field of study. Health Services Wake Forest Baptist Health, Winston-Salem, NC Which is Synopsis: Venous thromboembolism (VTE) prophylaxis better: Open, Robert L. Coleman, MD interventions in gynecologic surgery are meritorious, supported Professor, University of laparoscopic, by Level 1 evidence and the subject of multiple guidelines, including Texas; M.D. Anderson Cancer Center, Houston or robotic? those published by the American College of Obstetricians and Gynecologists. However, new evidence suggests nearly Alison Edelman, MD, MPH page 60 Associate Professor, one-third of women undergoing hysterectomy in this country Assistant Director of the still receive no VTE prophylaxis, placing thousands of women at Family Planning Fellowship Special Department of Obstetrics & unnecessary risk for preventable morbidity. Gynecology, Oregon Health feature: & Science University, Portland Do we have a Source: Wright JD, et al. Quality of perioperative venous thromboembolism John C. Hobbins, MD problem? prophylaxis in gynecologic surgery. Obstet Gynecol 2011;118:978-986. Professor, Department of Obstetrics and Gynecology, Obesity and University of Colorado Health contraception he objective of this study was to estimate the use of vte pro- Sciences Center, Denver page 61 Tphylaxis in women undergoing major gynecologic surgery and to Frank W.
    [Show full text]
  • Contraception for Women with Diabetes
    Care Plan ning : This leaflet should only be used with the ongoing advice from your Diabetes Team, as part of your plan of care . Contraception for . Women with Diabetes It is very important to plan your pregnancy if you have diabetes! Good blood glucose control before and throughout pregnancy cuts down the chance of problems for both you and your baby. We recommend that you discuss your plans to be become pregnant with your Diabetes Care Team at the earliest opportunity. This booklet aims to help you make your contraceptive choice. You may not be aware of all the options. Feel free to read the sections which appeal to you. • How does having diabetes affect your choice? Where to get help: • How does contraception fail? Your Diabetes team contact - • Why does contraception fail? Name: …………………………. • What are the different methods of contraception? ……………………………. Your Midwifery Team contact- a. Combined Pill (OCP) Name: …………………………. b. Progesterone-only Pill (POP) c. Contraceptive Patch …………………………….. d. Barrier Method Local Hospital Contact No.- e. Contraceptive Injection Nam e :……………………… f. Contraceptive Implants Diabetes in Pregnancy Advisory Group g. Intrauterine Devices (IUD, coil) ……………………………. h. Hormone Releasing System (IUS) i. Natural Methods Other: j. Sterilisation Name :……………………… © Perinatal Institute, Crystal Court, Aston Cross, k. Emergency Contraception Birmingham, B6 5RQ. Website: www.pi.nhs.uk ……………………………. Tel: 0121 687 3400 Email: [email protected] Version 12.1 (June 2012) • How does having diabetes affect your choice? K. Emergency contraception In general, women with diabetes can choose from the full This is urgently needed if you do not want to become range of options.
    [Show full text]
  • Acne, Accutanetm and You
    Acne, AccutaneTM and You www.AcneandU.ca Your source for ACCUTANETM ROCHE® (isotretinoin) information and resources. About Acne Important information about this guide Your doctor has prescribed ACCUTANE™ ROCHE® (isotretinoin) to treat your severe acne. Before your next appointment with your doctor: P Read this guide book § You will learn how to take ACCUTANE, its common side effects and important safety information about ACCUTANE P If you’re female, carefully read through the Pregnancy Prevention section of this guide § You must talk to your doctor about using birth control while taking ACCUTANE with your doctor § Choose two effective forms of birth control that you will use together P Write down your questions § If you have any questions about taking ACCUTANE, be sure to discuss them with your doctor at your next appointment P Read and sign the Informed Consent Form at the back of this booklet § If you are female, you must read and sign Part I and Part II of the form § If you are male, you must read and sign Part I of the form § If you are under the age of 16, one of your parents or your guardian must read and sign the document for you P Give one copy of your signed Informed Consent Form to your doctor § Your doctor must keep a signed copy of the Informed Consent Form in your medical file § You should keep the other copy of your signed Informed Consent Form For more information Call the birth control counselling line toll-free at 1-877-333-2263 or visit the ACCUTANE website at www.AcneandU.ca.
    [Show full text]
  • How Does VTE Risk for the Patch and Vaginal Ring Compare with Oral
    Evidence Based Answers CLINICAL INQUIRIES from the Family Physicians Inquiries Network Tricia C. Elliott, MD Baylor-Kelsey-Seybold Family How does VTE risk for the Medicine Residency Program, Houston patch and vaginal ring compare Cathy C. Montoya, MLS Department of Family and Community Medicine, with oral contraceptives? Baylor College of Medicine, Houston Evidence-based answer Evidence is confl icting with regard to high serum ethinyl estradiol (EE) level the comparative frequency of venous (strength of recommendation [SOR]: C, thrombolic events (VTE) among women confl icting cohort case-control studies). using the transdermal patch when The vaginal ring has a risk of VTE compared to an oral contraceptive (OC), comparable to that of an OC (SOR: B, ® even though the patch Dowdenproduces a relatively Health 1 comparative Media study). ClinicalCopyright commentaryFor personal use only For now, base decisions ring appeals to women who have had on patient preference diffi culty with OCs and need a simpler This review points out that we don’t dosing regimen to improve compliance. FAST TRACK have enough evidence to make a strong The choice between an oral estrogen- All estrogen- recommendation about oral or nonoral containing contraceptive and the patch estrogen-containing contraceptives based or ring should be based on the patient’s containing on the risk of thromboembolic disease. All preference, not the risk of thromboembolic contraceptives estrogen-containing contraceptives have disease, until we have evidence to suggest have similar side- similar side-effect profi les, regardless of the otherwise. route of administration. effect profi les, Richard Williams, MD In my experience, the patch or University of Nevada School of Medicine, Reno regardless of the route of administration ❚ Evidence summary update to the labeling of the Ortho- Two nonoral estrogen-progestin contra- Evra contraceptive patch, reporting ceptives have been approved by the US increased systemic estrogen exposure, Food and Drug Administration (FDA).
    [Show full text]
  • CONTRACEPTION How Much of a Risk Is Unplanned Pregnancy? • Almost Half of All Pregnancies in the United States Are Unplanned
    THINGS YOU SHOULD In the Clinic Annals of Internal Medicine KNOW ABOUT CONTRACEPTION How much of a risk is unplanned pregnancy? • Almost half of all pregnancies in the United States are unplanned. • Unplanned pregnancy increases the risk for problems for both the mother and the baby. • Women of all ages may have unplanned pregnancies. • Some groups are at a higher risk, including teens and people living in poverty. • Four out of five pregnancies among teenage women are unplanned. How can unplanned pregnancy be prevented? • Most women of reproductive age in the United States use contraception (birth control). • Several safe and effective methods are available. • Contraceptives are divided into hormonal and nonhormonal methods. • Most hormonal contraceptives work by suppressing ovulation. What type is right for you? • Intrauterine devices (IUDs) work by preventing • Many factors are considered when choosing birth sperm from fertilizing an egg. control, including whether you wish to become • Nonhormonal methods work by preventing sperm pregnant sometime in the future. from entering the cervix. • Long-acting methods, such as the IUD, are generally more reliable than short-acting methods like “the What types of birth control are pill” (which must be taken daily). • Medical conditions and other considerations may available? influence choice. • Combined or progesterone-only hormonal oral • Women who are overweight or smoke may face an contraceptive pills. increased risk for blood clot or stroke from hormonal • IUDs (levonorgestrel-releasing and copper). contraceptives. • Hormonal implant, contraceptive patch, or vaginal ring. • If you have sex without birth control, emergency • Barrier methods, including the male and female contraception is available to prevent pregnancy.
    [Show full text]
  • Contraceptive Patch
    your guide to the contraceptive patch Helping you choose the method of contraception that is best for you contraceptive patch contraceptivecontraceptive patch patch contraceptivecontraceptive patch contraceptive patch contraceptive contraceptivepatchcontraceptive patch patch contraceptive patch contraceptivecontraceptive patch patch contracepcontraceptive patch contraceptive patch contraceptivecontraceptivecontraceptive patch patch patch 2 3 How effective is the patch? The contraceptive How effective any contraceptive is depends on how old you are, how often you have sex and whether you follow the instructions. patch If 100 sexually active women don’t use any The contraceptive patch is a small, thin, beige contraception 80 to 90 will become pregnant in coloured patch, nearly 5cm x 5cm in size. You stick a year. it on your skin and it releases two hormones – If used correctly and according to instructions estrogen and progestogen. These are similar to the the patch is over 99 per cent effective. This means natural hormones that women produce in their less than one woman in 100 will get pregnant in ovaries and like those used in the combined pill. a year. If the patch is not used according to instructions, more women will become pregnant. Contents How effective is the patch?. ..........................................................3 What if I forget to put on a new patch at the end of How does the patch work? ..........................................................4 the patch-free week? .....................................................................14
    [Show full text]